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Hepatocyte growth factor (HGF) can be produced by various cells and
elicits multiple biological responses such as motility, proliferation, mor-
phogenesis and survival in a cell type-dependent fashion. Apart from its
physiological importance, HGF may contribute to many organ diseases 
[1-3]. We have already shown that conversely to routinely measured bio-
markers of myocardial injury, human HGF (hHGF) increases to high levels
in the very early phase of acute coronary syndrome (ACS) and then
decreases rapidly during the first 24 h of ACS [4]. As described in our pre-
vious article, we measured hHGF concentration only twice, namely at
admission and 24 h later [4]. We decided to establish the dynamicity of
hHGF level changes on the first day of myocardial injury and to determine
the usefulness of its measurement in the case of untimely complications.
In 4 patients with ST-segment elevation myocardial infarction (STEMI)
and in 2 patients with non ST-segment elevation myocardial infarction
(NSTEMI), who were eligible for coronary angiography and, possibly, pri-
mary percutaneous coronary intervention (PPCI), hHGF measurements
were repeated 10 times during the first day of ACS and once at discharge
from hospital (Figure 1). Each subject expressed their informed consent
to participate in the study. Patients’ informed consent and the protocol of
the study were approved by the Institutional Local Ethics Committee.
Patients’ detailed particulars are presented in the Table I.
Human HGF was determined in plasma using the Quantikine Elisa kit
from R&D Systems, Minneapolis, MN, USA. The mean value of hHGF eval-
uated in EDTA plasma using the Quantikine Elisa kit and presented in the
manufacturer’s brochure as a reference value was 787 pg/ml (range: 469-
1113 pg/ml). 
In the first measurement, as illustrated in the Figure 1, a marked increase
in hHGF levels was observed in STEMI patients. Very high values (maxi-
mally about 20 000 pg/ml) were reduced to almost normal values within
5 h from the first measurement. In NSTEMI patients, even in the first
assessment we did not observe very high levels of hHGF, and during the
first 24 h of ACS, hHGF levels were stable. Contrary to patients with an
uncomplicated acute course of STEMI, 2 patients with serious cardiovas-
cular events in the acute stage of myocardial infarction, namely cardiac
arrest and early reocclusion of the coronary artery, revealed a second
increase of hHGF levels during the first 24 h of ACS (Figure 1).
We have already revealed that during the first 24 h of ACS HGF showed
properties comparable with troponin I and N-terminal prohormone B-type
natriuretic peptide (NT-proBNP), which are routinely used as markers of
ischemic myocardial damage and risk stratification in patients with
Corresponding author:
Anna Konopka MD, PhD
Intensive Cardiac 
Therapy Clinic
Institute of Cardiology
42 Alpejska 
04-628 Warsaw, Poland
Phone: + 48 22 343 47 70
Fax: +48 22 815 42 67
E-mail: akonopka@ptkardio.pl
Letter to the Editor
Intensive Cardiac Therapy Clinic, Institute of Cardiology, Warsaw, Poland 
Submitted: 17 February 2012
Accepted: 27 February 2012
Arch Med Sci 2012; 8, 2: 389-391
DOI: 10.5114/aoms.2012.28571
Copyright © 2012 Termedia & Banachimpaired left ventricular function [4-7]. Troponin I
reached peak values and confirmed myocardial nec  -
ro  sis when hHGF levels were already at a normal 
level [4]. Now, the very high hHGF values were ob  ser  -
ved in patients admitted within the first 2 h of STEMI
presentation (patients 5 and 6) (Figure 1, Table I). In
this aspect, the observed changes in hHGF concen-
trations in the early stage of myocardial infarction
are a great advantage of this diagnostic method. 
The time from the onset of ACS symptoms to
treatment, effectiveness of reperfusion therapy
measured as grade of flow in the infarct-related
artery, and medical therapy applied during PPCI
influence the levels of biomarkers [5, 8]. We sup-
posed that in our study hHGF re-elevation was
connected with acute complications of ACS. Due
to the small number of patients we cannot defi-
nitely prove this relationship. We hope that sub-
sequent research will confirm our preliminary
observations. In conclusion, we found that: (1) in
all our patients the highest hHGF values were
observed at admission due to symptoms of acute
coronary syndrome, (2) hHGF concentrations were
reduced to normal values very quickly (within 
5 h from the first measurement), (3) severe com-
plications in the acute stage of STEMI most 
likely resulted in an additional increase in hHGF
levels. 
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Patient 123456  
Age [years] 70 56 66 61 72 39
Gender Male Male Male Male Female Male
Duration of chest pain [min] 370 570 900 160 125 120
Type of ACS and localization of MI (wall) STEMI NSTEMI STEMI NSTEMI STEMI STEMI
inferior and  anterior MI posterior  posterior and
posterior MI MI lateral MI
cTnI [ng/ml] – first day of ACS 0.23 6.54 4.78 0.11 0.01 0.03
cTnI [ng/ml] – second day of ACS 14.99 11.55 18.98 9.25 1.18 24.24
PPCI Yes No Yes No Yes Yes
Infarct-related artery CRX LAD CRX CRX
Stent implantation Yes No Yes No Yes No
Clopidogrel in loading dose 600 mg  Yes Yes Yes Yes Yes Yes
before PPCI
Aspirin [mg] 300 150 300 300 300 300
Abciximab during PPCI Yes No Yes No No No
Complications during acute stage of ACS CA (VF) No No No No CRX 
reocclusion 
during PCI
EF – second day of ACS [%] 46 55 60 60 70 50
ACS – acute coronary syndrome, MI – myocardial infarction, STEMI – ST-segment elevation myocardial infarction, NSTEMI – non-ST-segment ele-
vation myocardial infarction, cTnI – cardiac troponin I with diagnostic cut-point 0.1 ng/ml, PPCI – primary percutaneous coronary intervention,
CRX – circumflex coronary artery, LAD – left descending coronary artery, CA – cardiac arrest, VF – ventricular fibrillation, EF – ejection fraction
measured by echocardiography
Table I. Detailed description of six patients with ACS
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Figure 1. Human HGF concentrations in six patients
with ACS
VF – ventricular fibrillation, CRX – circumflex coronary artery,
pt – patient
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